{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:24:43Z","timestamp":1791915883043,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s13555-025-01465-4","type":"journal-article","created":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T13:06:23Z","timestamp":1752411983000},"page":"2553-2570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE\u00a0HEARD\u00a0I&II"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct04242446","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04242498","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7510-9428","authenticated-orcid":false,"given":"Vivian Y.","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-1142","authenticated-orcid":false,"given":"John R.","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6223-7001","authenticated-orcid":false,"given":"Hadar","family":"Lev-Tov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9740-6845","authenticated-orcid":false,"given":"Sylke","family":"Schneider-Burrus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-4385","authenticated-orcid":false,"given":"Martina L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-2493","authenticated-orcid":false,"given":"Koremasa","family":"Hayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3734-9607","authenticated-orcid":false,"given":"Linnea","family":"Thorlacius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-1492","authenticated-orcid":false,"given":"J\u00e9r\u00e9my","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Vaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0217-6313","authenticated-orcid":false,"given":"Bartosz","family":"Lukowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Rolleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-6342","authenticated-orcid":false,"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,13]]},"reference":[{"key":"1465_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s13555-023-01085-w","volume":"14","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Kirby J, Ingram JR, et al. Burden of hidradenitis suppurativa: a systematic literature review of patient reported outcomes. Dermatol Ther (Heidelb). 2024;14:83\u201398.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1465_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11916-017-0647-3","volume":"21","author":"ZS Patel","year":"2017","unstructured":"Patel ZS, Hoffman LK, Buse DC, et al. Pain, psychological comorbidities, disability, and impaired quality of life in hidradenitis suppurativa [corrected]. Curr Pain Headache Rep. 2017;21:49.","journal-title":"Curr Pain Headache Rep"},{"key":"1465_CR3","doi-asserted-by":"publisher","first-page":"6709","DOI":"10.3390\/ijerph18136709","volume":"18","author":"T Montero-Vilchez","year":"2021","unstructured":"Montero-Vilchez T, Diaz-Calvillo P, Rodriguez-Pozo JA, et al. The burden of hidradenitis suppurativa signs and symptoms in quality of life: systematic review and meta-analysis. Int J Environ Res Public Health. 2021;18:6709.","journal-title":"Int J Environ Res Public Health"},{"key":"1465_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000502139","volume":"236","author":"A Molina-Leyva","year":"2020","unstructured":"Molina-Leyva A, Cuenca-Barrales C. Pruritus and malodour in patients with hidradenitis suppurativa: impact on quality of life and clinical features associated with symptom severity. Dermatology. 2020;236:59\u201365.","journal-title":"Dermatology"},{"key":"1465_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/bjd\/ljac018","volume":"188","author":"LAV Orenstein","year":"2023","unstructured":"Orenstein LAV, Salame N, Siira MR, et al. Pain experiences among those living with hidradenitis suppurativa: a qualitative study. Br J Dermatol. 2023;188:41\u201351.","journal-title":"Br J Dermatol"},{"key":"1465_CR6","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","volume":"86","author":"A Garg","year":"2022","unstructured":"Garg A, Malviya N, Strunk A, et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2022;86:1092\u2013101.","journal-title":"J Am Acad Dermatol"},{"key":"1465_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000107625","volume":"215","author":"S Salek","year":"2007","unstructured":"Salek S, Roberts A, Finlay AY. The practical reality of using a patient-reported outcome measure in a routine dermatology clinic. Dermatology. 2007;215:315\u20139.","journal-title":"Dermatology"},{"key":"1465_CR8","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/bjd.13270","volume":"171","author":"AB Kimball","year":"2014","unstructured":"Kimball AB, Jemec GB, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171:1434\u201342.","journal-title":"Br J Dermatol"},{"key":"1465_CR9","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.16672","volume":"179","author":"L Thorlacius","year":"2018","unstructured":"Thorlacius L, Ingram JR, Villumsen B, et al. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. Br J Dermatol. 2018;179:642\u201350.","journal-title":"Br J Dermatol"},{"key":"1465_CR10","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE\u00a0HEARD\u00a0I and BE\u00a0HEARD\u00a0II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase\u00a03 trials. Lancet. 2024;403:2504\u201319.","journal-title":"Lancet"},{"key":"1465_CR11","doi-asserted-by":"publisher","first-page":"S489","DOI":"10.1016\/j.jval.2023.09.2642","volume":"26","author":"JR Ingram","year":"2023","unstructured":"Ingram JR, Kirby JS, Lambert J, et al. PCR205 Determination of ranges of HSSDD & HSSQ scores defining clinically meaningful within-patient improvement thresholds and severity levels. Value Health. 2023;26:S489.","journal-title":"Value Health"},{"key":"1465_CR12","doi-asserted-by":"publisher","first-page":"S477","DOI":"10.1016\/j.jval.2023.09.2587","volume":"26","author":"JS Kirby","year":"2023","unstructured":"Kirby JS, Ingram JR, Lambert J, et al. PCR149 Determination of ranges of HiSQOL scores defining clinically meaningful within-patient improvement thresholds and severity levels. Value Health. 2023;26:S477.","journal-title":"Value Health"},{"key":"1465_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"S Glatt","year":"2018","unstructured":"Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523\u201332.","journal-title":"Ann Rheum Dis"},{"key":"1465_CR14","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/jdv.16147","volume":"34","author":"CC Zouboulis","year":"2020","unstructured":"Zouboulis CC, Nogueira da Costa A, Makrantonaki E, et al. Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2020;34:846\u201361.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1465_CR15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","volume":"65","author":"C Schlapbach","year":"2011","unstructured":"Schlapbach C, H\u00e4nni T, Yawalkar N, et al. Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65:790\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1465_CR16","doi-asserted-by":"crossref","unstructured":"Rastrick J, Edwards H, Ferecsk\u00f3 AS, et al. The roles of IL-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples. Br J Dermatol. 2025;192(4):660\u201371.","DOI":"10.1093\/bjd\/ljae442"},{"key":"1465_CR17","unstructured":"US Food and Drug Administration. Bimekizumab Prescribing Information. https:\/\/www.ucb-usa.com\/bimzelx-prescribing-information.pdf. Accessed 29 Nov 2024."},{"key":"1465_CR18","unstructured":"European Medicines Agency. Bimekizumab Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bimzelx-epar-product-information_en.pdf. Accessed 29 Nov 2024."},{"key":"1465_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000496234","volume":"5","author":"L Thorlacius","year":"2019","unstructured":"Thorlacius L, Esmann S, Miller I, et al. Development of HiSQOL: a hidradenitis suppurativa-specific quality of life instrument. Skin Appendage Disord. 2019;5:221\u20139.","journal-title":"Skin Appendage Disord"},{"key":"1465_CR20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bjd.18692","volume":"183","author":"JS Kirby","year":"2020","unstructured":"Kirby JS, Thorlacius L, Villumsen B, et al. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol. 2020;183:340\u20138.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1465_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000534463","volume":"240","author":"JR Ingram","year":"2024","unstructured":"Ingram JR, Ciaravino V, Rolleri R, et al. Electronic patient-reported outcomes in hidradenitis suppurativa: content validity and usability of the electronic Hidradenitis Suppurativa Symptom Daily Diary, Hidradenitis Suppurativa Symptom Questionnaire and Hidradenitis Suppurativa Quality of Life Questionnaire. Dermatology. 2024;240(1):65\u201376.","journal-title":"Dermatology"},{"key":"1465_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"1465_CR23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125:659\u201364.","journal-title":"J Invest Dermatol"},{"key":"1465_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230:27\u201333.","journal-title":"Dermatology"},{"key":"1465_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat R, Jemec GBE, Matusiak \u0141, et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6:18.","journal-title":"Nat Rev Dis Primers"},{"key":"1465_CR26","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1111\/bjd.16603","volume":"183","author":"\u0141 Matusiak","year":"2020","unstructured":"Matusiak \u0141. Profound consequences of hidradenitis suppurativa: a review. Br J Dermatol. 2020;183:e171\u20137.","journal-title":"Br J Dermatol"},{"key":"1465_CR27","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","volume":"82","author":"A Garg","year":"2020","unstructured":"Garg A, Neuren E, Cha D, et al. Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82:366\u201376.","journal-title":"J Am Acad Dermatol"},{"key":"1465_CR28","unstructured":"FDA. Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims; availability. 2009. https:\/\/www.federalregister.gov\/documents\/2009\/12\/09\/E9-29273\/guidance-for-industry-on-patient-reported-outcome-measures-use-in-medical-product-development-to. Accessed 26 June 24."},{"key":"1465_CR29","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s13555-025-01343-z","volume":"15","author":"LAV Orenstein","year":"2025","unstructured":"Orenstein LAV, Shi VY, Lev-Tov H, et al. 0016 Bimekizumab 2\u2011Year impact on HSSQ skin pain in moderate to severe HS: Data from BE HEARD EXT. Dermatol Ther (Heidelb). 2025;15:483\u2013562.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1465_CR30","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.3390\/jcm11133813","volume":"11","author":"P Agarwal","year":"2022","unstructured":"Agarwal P, Lunge SB, Shetty NS, et al. Itch in hidradenitis suppurativa\/acne inversa: a systematic review. J Clin Med. 2022;11:3813.","journal-title":"J Clin Med"},{"key":"1465_CR31","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.jaad.2020.05.007","volume":"83","author":"JW Frew","year":"2020","unstructured":"Frew JW, Navrazhina K, Grand D, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study. J Am Acad Dermatol. 2020;83:1341\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1465_CR32","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1177\/1203475417745826","volume":"22","author":"A Alavi","year":"2018","unstructured":"Alavi A, Farzanfar D, Lee RK, et al. The contribution of malodour in quality of life of patients with hidradenitis suppurativa. J Cutan Med Surg. 2018;22:166\u201374.","journal-title":"J Cutan Med Surg"},{"key":"1465_CR33","doi-asserted-by":"publisher","first-page":"AB66","DOI":"10.1016\/j.jaad.2024.07.270","volume":"91","author":"I Cutcutache","year":"2024","unstructured":"Cutcutache I, Rastrick J, Ferecsko A, et al. 52693 Normalization of molecular signatures associated with pruritis in plaque psoriasis correlate with itch resolution following bimekizumab treatment. JAAD. 2024;91:AB66.","journal-title":"JAAD"},{"key":"1465_CR34","unstructured":"FDA. Patient-focused drug development: methods to identify what is important to patients. 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients. Accessed 20 Aug 2024."},{"key":"1465_CR35","unstructured":"FDA. Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making. 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory. Accessed 20 Aug 2024."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01465-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01465-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01465-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T07:02:38Z","timestamp":1757228558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01465-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,13]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1465"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01465-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,13]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Vivian Y. Shi: On the board of directors for the Hidradenitis Suppurativa Foundation (HSF), advisor for the National Eczema Association, shareholder of Learn Health and has served as an advisory board member, investigator, speaker, and\/or received research funding from AbbVie, Altus Lab\/cQuell, Alumis, Aristea Therapeutics, Boehringer Ingelheim, Burt\u2019s Bees, Dermira, Eli Lilly and Company, Galderma, Genentech, GpSkin, Incyte, Kiniksa, LEO Pharma, Menlo Therapeutics, MYOR, Novartis, Pfizer, Polyfins Technology, Regeneron, Sanofi Genzyme, Skin Actives Scientific, Sun Pharma, Target-PharmaSolutions and UCB. John R. Ingram: Received a stipend as immediate past-Editor-in-Chief of the British Journal of Dermatology and an authorship honorarium from UpToDate. Consultant for AbbVie, Boehringer Ingelheim, Cantargia, ChemoCentryx, Citryll, Engitix, Incyte, Insmed, Kymera Therapeutics, MoonLake Immunotherapeutics, Novartis, UCB, UNION Therapeutics and Viela Bio. Co-copyright holder of HiSQOL, Investigator Global Assessment and Patient Global Assessment instruments for HS and department receives income from copyright of the Dermatology Life Quality Index (DLQI) and related instruments. Affiliated with the European Hidradenitis Suppurativa Foundation (EHSF) e.V., Dessau, Germany. Hadar Lev-Tov: Consultant for Novartis and UCB. Sylke Schneider-Burrus: Received honoraria for participation in advisory boards, in clinical trials, and\/or as speaker from AbbVie, Biogen, Boehringer Ingelheim, Hexal, MoonLake Immunotherapeutics, Novartis, Sanofi and UCB. Seth Forman: Investigator\/consultant and\/or advisor to AbbVie, Aclaris, Almirall, Arcutis, ASLAN Pharmaceuticals, BioHaven, Boehringer Ingelheim, Bristol Myers Squibb, Cali, Concert, Eli Lilly and Company, Evelo, Horizon Therapeutics, Incyte, Janssen, Merck, Pfizer, UCB and Vertex. Martina L. Porter: Consultant and investigator for AbbVie, Avalo Therapeutics, Aristea, Eli Lilly and Company, Incyte, Janssen, MoonLake Immunotherapeutics, Novartis, Pfizer, Prometheus, Sanofi, Sonoma Biotherapeutics and UCB; consultant for Alumis, FIDE, Trifecta Clinical\/WCG and ZuraBio; investigator for Anaptys Bio, Bayer, Bristol Myers Squibb, OASIS Pharmaceuticals and Regeneron; received royalties from Beth Israel Deaconess Medical Center. Koremasa Hayama: Principal investigator for and consultancy\/advisory boards from AbbVie, Boehringer Ingelheim and Novartis; speaker fees\/grants from AbbVie, Boehringer Ingelheim, Eisai, Novartis and UCB. Linnea Thorlacius: Co\u2011copyright holder of HIDE\u00a9 (HIdradenitis suppurativa DrainagE), HiSQOL\u00a9 (Hidradenitis Suppurativa Quality of Life) and HS-IGA\u00a9 (Hidradenitis Suppurativa Investigator Global Assessment). Investigator for Incyte, Janssen, Novartis and UCB. Speaker fees from UCB. J\u00e9r\u00e9my Lambert, Tom Vaux, Bartosz Lukowski, Robert L. Rolleri: Employees and shareholders of UCB. Jacek C. Szepietowski: Consultant and advisory board member of AbbVie, LEO Pharma, Novartis, Pierre Fabre, Sanofi-Genzyme, UCB, Sandoz, Almirall, Boehringer Ingelheim and Galderma; speaker for AbbVie, Almirall, Boehringer Ingelheim, Janssen, Eli Lilly and Company, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Sanofi Genzyme and UCB; investigator for AbbVie, Acelyrin, Almirall Hermal, Amgen, AnaptysBio, Argenx, Aslan, Boehringer Ingelheim, Biocom, Bio Thera, Bristol Myers Squibb, Celltrion, CuraTeQ Biologics, DICE Therapeutics, Eli Lilly and Company, Helm AG, Galapagos, Galderma, Janssen, Incyte, InflaRX, Kiniksa, Kymab Limited, LEO Pharma, MedImmune, Menlo Therapeutics, Merck, Moonlake, Novartis, Pierre Fabre, Pfizer, Regeneron Pharmaceuticals, Takeda, Teva, Trevi Therapeutics, UCB, Uni Therapeutics and Ventyx Bioscience; editorial board member of Dermatology and Therapy; was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Affiliated with the European Hidradenitis Suppurativa Foundation (EHSF) e.V., Dessau, Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol, amendments and patient informed consent were reviewed by a national, regional or Independent Ethics Committee (IEC) or Institutional Review Board (IRB). This study was conducted in accordance with the current version of the applicable regulatory and International Conference on Harmonisation (ICH)\u2013Good Clinical Practice (GCP) requirements, the ethical principles that have their origin in the principles of the Declaration of Helsinki, and the local laws of the countries involved. Ethics approval was obtained from the relevant institutional review boards at participating sites. BE\u00a0HEARD\u00a0I&II have previously been published and full ethical approval was acquired for both of these studies. All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}